Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 15 Feb 2018
Price : $35 *
At a glance
- Drugs Oprozomib (Primary) ; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Onyx Pharmaceuticals
- 02 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 05 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 25 Feb 2014 New source identified and integrated (ClinicalTrials.gov record; NCT02072863).